Shift Work Sleep DisorderRESTNCT07785960
Recovery and Early Sleep Tracking Using the SuperPatch REM Patch
A study testing SuperPatch REM Patch in people with Shift Work Sleep Disorder and Shift Work Type Circadian Rhythm Sleep Disorder, run by SuperPatch Limited LLC at 1 site in United Kingdom.
Trial summary
A Phase 1 Feasibility Study of the SuperPatch REM Patch for Post-Night-Shift Sleep Recovery in NHS Doctors Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Shift Work Sleep Disorder, Shift Work Type Circadian Rhythm Sleep Disorder, Shift Work Sleep Disorders
- What is being tested?
- SuperPatch REM Patch
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 15 May 2026to Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult doctors (≥18 years) working regular night shifts
- Able to provide informed consent and comply with remote study procedures
- Willing to wear a sleep-tracking wearable during the study period
- Willing to apply an adhesive study patch during designated post-shift sleep episodes
Who cannot join
- Known allergy/sensitivity to adhesives or significant dermatologic condition affecting patch placement
- Concurrent use of another device adhered to the body at the same site that could interfere with patch placement
- Any condition judged by investigators to make participation unsafe or data uninterpretable (e.g., acute illness impacting sleep)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
A Phase 1 Feasibility Study of the SuperPatch REM Patch for Post-Night-Shift Sleep Recovery in NHS Doctors
Read the detailed description
Night-shift work is associated with disrupted sleep timing, reduced sleep quality, and impaired recovery. The SuperPatch REM Patch is a drug-free, non-invasive vibrotactile technology intended to support recovery signals around sleep, including sleep staging and autonomic metrics. This Phase 1 study is designed to determine feasibility and acceptability in a high-need population (post-night shift NHS doctors), and to estimate preliminary effect sizes on objective wearable sleep metrics and validated subjective recovery outcomes to inform a future double-blind RCT.
- Conditions
- Shift Work Sleep Disorder, Shift Work Type Circadian Rhythm Sleep Disorder, Shift Work Sleep Disorders
- Being tested
- SuperPatch REM Patch, Sham REM Patch
- Keywords
- shift work disorder, insomnia, SuperPatch, REM Patch, Haptic Vibrotactile Trigger Technology
- Medical subject headings
- Sleep Disorders, Circadian Rhythm, Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SuperPatch REM PatchDevice
Also called REM Patch
A drug-free, non-invasive vibrotactile (haptic) patch applied to the skin immediately prior to post-night-shift sleep and removed upon waking, intended to support recovery signals around sleep including sleep staging and autonomic metrics. Applied across 3-4 post-night-shift sleep episodes.
Sham REM PatchDevice
Also called Placebo patch
A visually identical sham patch without vibrotactile technology, applied using the same timing, wear duration, and procedure as the active patch.
| Study group | Role | What they receive |
|---|---|---|
| Active REM Patch (Vibrotactile/Haptic) | Active comparator | Participants apply the SuperPatch REM Patch, a drug-free vibrotactile (haptic) device, before post-night-shift sleep for 3-4 sleep episodes. Receives: Device: SuperPatch REM Patch |
| Sham REM Patch (Placebo) | Sham comparator | Participants apply a visually identical sham patch without vibrotactile technology, following the same timing and duration as the Active arm. Receives: Device: Sham REM Patch |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of study procedures (recruitment)
Number of participants enrolled per week during the recruitment period. Unit of Measure: Participants/week
Measured: Time Frame: Throughout the recruitment period, up to 8 weeks
Feasibility of Study Procedures (Retention Rate)
Percentage of enrolled participants who complete the study. Unit of Measure: Percentage of participants
Measured: Time Frame: Throughout the recruitment period, up to 8 weeks
Feasibility of Study Procedures (Wearable Compliance Rate)
Percentage of expected post-night-shift sleep episodes with a valid wearable sleep record, out of 3-4 expected post-night-shift sleep episodes with a valid wearable sleep record, out of 3-4 expected episodes per participant.
Measured: Time Frame: Throughout the recruitment period, up to 8 weeks
Feasibility of Study Procedures (Survey Completion Rate)
Percentage of expected episode surveys (PROMIS Sleep Disturbance and Karolinska Sleepiness Scale) completed, out of 3-4 expected episodes per participant.
Measured: Time Frame: Throughout the recruitment period, up to 8 weeks
Feasibility of Study Procedures (Patch Adherence Rate)
Percentage of post-night-shift sleep episodes in which the patch was worn for the full designated wear time.
Unit of Measure: Percentage of episodes
Measured: Time Frame: Throughout the recruitment period, up to 8 weeks
Total Sleep Time (TST)
Wearable-derived total sleep time per post-night-shift sleep episode, compared between Active and Sham REM Patch groups.
Unit of Measure: Minutes
Measured: Each post-night-shift sleep episode, up to 4 episodes per participant
Sleep Efficiency
Wearable-derived sleep efficiency (percentage of time in bed spent asleep) per episode, compared between groups.
Unit of Measure: Percentage
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
REM Sleep Duration
Wearable-derived REM sleep duration per episode, compared between Active and Sham REM Patch groups.
Unit of Measure: Minutes
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Deep Sleep Duration
Wearable-derived deep (slow-wave) sleep duration per episode, compared between groups.
Unit of Measure: Minutes
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Average Sleeping Heart Rate
Wearable-derived average heart rate during the sleep episode, compared between Active and Sham REM Patch groups.
Unit of Measure: Beats per minute
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Heart Rate Variability (HRV)
Wearable-derived heart rate variability during the sleep episode, compared between groups.
Unit of Measure: Milliseconds
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Secondary outcomes (8)
PROMIS Sleep Disturbance score
Patient-reported sleep quality/disturbance, collected via the PROMIS Sleep Disturbance questionnaire (episode-adapted wording), completed upon waking after each post-night-shift sleep episode.
Unit of Measure: T-score on a scale of [confirm min-max for the specific short form used, e.g., 30.7 to 76.5 for the standard 8-item PROMIS Sleep Disturbance short form]
Measured: Upon waking, at each of 3-4 post-night-shift sleep episodes per participant
Karolinska Sleepiness Scale (KSS) score
Self-rated state sleepiness at waking, measured using the Karolinska Sleepiness Scale, a brief single-item scale validated in shift-work populations.
Unit of Measure: Score on a scale of 1 (extremely alert) to 9 (extremely sleepy, fighting sleep); higher scores indicate greater sleepiness (worse outcome)
Measured: Upon waking, at each of 3-4 post-night-shift sleep episodes per participant
Sleep Onset Latency
Wearable-derived time from lights-out to sleep onset, where supported by the participant's device.
Unit of Measure: Minutes
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Incidence of Skin Irritation and Adverse Events Associated with Patch Use
Frequency and severity of skin irritation and other adverse events (e.g., headache, dizziness) associated with wear of either the Active or Sham REM Patch, captured via daily/episode adherence checks and adverse event reporting.
Unit of Measure: Number of adverse events
Measured: Time Frame: From first patch application through study completion, up to 8 weeks
Wake After Sleep Onset (WASO)
Wearable-derived total wake time after initial sleep onset, where supported by the participant's device.
Unit of Measure: Minutes
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Respiratory Rate During Sleep
Wearable-derived average respiratory rate during the sleep episode, where supported by the participant's device.
Unit of Measure: Breaths per minute
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Peripheral Oxygen Saturation (SpO₂) During Sleep
Wearable-derived average SpO₂ during the sleep episode, where supported by the participant's device.
Unit of Measure: Percentage
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Device-Reported Stress Score
Proprietary wearable-derived stress index, where supported by the participant's device; scoring scale is device-specific.
Unit of Measure: Score on device-specific scale
Measured: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2026
- Study start15 May 2026
- Primary completionOct 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Shift Work Sleep DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Non-randomized, comparative, parallel-group; double-blind
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SuperPatch Limited LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Clarity Science LLC, Vichag Healthcare Research
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07785960
- Sponsor's protocol ID
- REST-001
- Acronym
- REST
- Status last verified
- Aug 2026
- First submitted
- 19 Aug 2026
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Here's a short, submission-ready description you can paste into the IPD Sharing Statement field: Individual participant data will not be shared. This is a small Phase 1 feasibility study (N=20) conducted within a narrowly defined population (NHS doctors on night-shift rotations in the UK), where the limited sample size and specificity of the population create a meaningful risk of participant re-identification, even after de-identification. Data collected are intended solely to assess feasibility and generate preliminary effect-size estimates to inform the design of a future randomized controlled trial, consistent with the scope of participant consent obtained for this study. Data will be handled in accordance with UK GDPR, including data minimization and pseudonymization safeguards.
Publications
Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990 May;52(1-2):29-37. doi: 10.3109/00207459008994241.
PubMed 2265922Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, Johnston KL, Pilkonis PA. Development of short forms from the PROMIS sleep disturbance and Sleep-Related Impairment item banks. Behav Sleep Med. 2011 Dec 28;10(1):6-24. doi: 10.1080/15402002.2012.636266.
PubMed 22250775Gudin J, Dietze D, Dhaliwal G, Hurwitz P. "Haptic Vibrotactile Trigger Technology: Disrupting the Neuromatrix to Reduce Pain Severity and Interference: Results from the HARMONI Study." Anesth Pain Res. 2022;6(1).
Fason J, Gudin J, Hurwitz P. Decreased anxiety through haptic technology patch usage: A case-control comparison. J Family Med Prim Care. 2025 Aug;14(8):3529-3537. doi: 10.4103/jfmpc.jfmpc_1981_24. Epub 2025 Sep 24.
PubMed 41041253Doghramji P, Dietze A. "Improving Sleep and Quality of Life after Use of a Haptic Vibrotactile Trigger Technology, Drug-Free, Topical Patch: Results from the HARMONI Study." Int J Family Med Healthcare. 2023;2(1).
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Recovery and Early Sleep Tracking Using the SuperPatch REM Patch
- ClinicalTrials.gov ID
- NCT07785960
- Acronym / sponsor ID
- REST / REST-001
- Conditions
- Shift Work Sleep Disorder, Shift Work Type Circadian Rhythm Sleep Disorder, Shift Work Sleep Disorders
- Keywords
- shift work disorder, insomnia, SuperPatch, REM Patch, Haptic Vibrotactile Trigger Technology
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- SuperPatch Limited LLCIndustry (pharma, biotech, devices)
- Collaborators
- Clarity Science LLC, Vichag Healthcare Research
- Study start
- 15 May 2026 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 25 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Phase 1 Feasibility Study of the SuperPatch REM Patch for Post-Night-Shift Sleep Recovery in NHS Doctors
Detailed description
Night-shift work is associated with disrupted sleep timing, reduced sleep quality, and impaired recovery. The SuperPatch REM Patch is a drug-free, non-invasive vibrotactile technology intended to support recovery signals around sleep, including sleep staging and autonomic metrics. This Phase 1 study is designed to determine feasibility and acceptability in a high-need population (post-night shift NHS doctors), and to estimate preliminary effect sizes on objective wearable sleep metrics and validated subjective recovery outcomes to inform a future double-blind RCT.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Non-randomized, comparative, parallel-group; double-blind
| Arm | Type | Receives |
|---|---|---|
| Active REM Patch (Vibrotactile/Haptic) | Active comparator | Device: SuperPatch REM PatchParticipants apply the SuperPatch REM Patch, a drug-free vibrotactile (haptic) device, before post-night-shift sleep for 3-4 sleep episodes. |
| Sham REM Patch (Placebo) | Sham comparator | Device: Sham REM PatchParticipants apply a visually identical sham patch without vibrotactile technology, following the same timing and duration as the Active arm. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult doctors (≥18 years) working regular night shifts
- Able to provide informed consent and comply with remote study procedures
- Willing to wear a sleep-tracking wearable during the study period
- Willing to apply an adhesive study patch during designated post-shift sleep episodes
Key exclusion criteria (3 listed)
- Known allergy/sensitivity to adhesives or significant dermatologic condition affecting patch placement
- Concurrent use of another device adhered to the body at the same site that could interfere with patch placement
- Any condition judged by investigators to make participation unsafe or data uninterpretable (e.g., acute illness impacting sleep)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SuperPatch REM PatchAlso: REM PatchA drug-free, non-invasive vibrotactile (haptic) patch applied to the skin immediately prior to post-night-shift sleep and removed upon waking, intended to support recovery signals around sleep including sleep staging and autonomic metrics. Applied across 3-4 post-night-shift sleep episodes. | Device | Active REM Patch (Vibrotactile/Haptic) |
| Sham REM PatchAlso: Placebo patchA visually identical sham patch without vibrotactile technology, applied using the same timing, wear duration, and procedure as the active patch. | Device | Sham REM Patch (Placebo) |
Primary outcome
Feasibility of study procedures (recruitment)
Time frame: Time Frame: Throughout the recruitment period, up to 8 weeks
Number of participants enrolled per week during the recruitment period. Unit of Measure: Participants/week
Feasibility of Study Procedures (Retention Rate)
Time frame: Time Frame: Throughout the recruitment period, up to 8 weeks
Percentage of enrolled participants who complete the study. Unit of Measure: Percentage of participants
Feasibility of Study Procedures (Wearable Compliance Rate)
Time frame: Time Frame: Throughout the recruitment period, up to 8 weeks
Percentage of expected post-night-shift sleep episodes with a valid wearable sleep record, out of 3-4 expected post-night-shift sleep episodes with a valid wearable sleep record, out of 3-4 expected episodes per participant.
Feasibility of Study Procedures (Survey Completion Rate)
Time frame: Time Frame: Throughout the recruitment period, up to 8 weeks
Percentage of expected episode surveys (PROMIS Sleep Disturbance and Karolinska Sleepiness Scale) completed, out of 3-4 expected episodes per participant.
Feasibility of Study Procedures (Patch Adherence Rate)
Time frame: Time Frame: Throughout the recruitment period, up to 8 weeks
Percentage of post-night-shift sleep episodes in which the patch was worn for the full designated wear time. Unit of Measure: Percentage of episodes
Total Sleep Time (TST)
Time frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Wearable-derived total sleep time per post-night-shift sleep episode, compared between Active and Sham REM Patch groups. Unit of Measure: Minutes
Sleep Efficiency
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Wearable-derived sleep efficiency (percentage of time in bed spent asleep) per episode, compared between groups. Unit of Measure: Percentage
REM Sleep Duration
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Wearable-derived REM sleep duration per episode, compared between Active and Sham REM Patch groups. Unit of Measure: Minutes
Deep Sleep Duration
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Wearable-derived deep (slow-wave) sleep duration per episode, compared between groups. Unit of Measure: Minutes
Average Sleeping Heart Rate
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Wearable-derived average heart rate during the sleep episode, compared between Active and Sham REM Patch groups. Unit of Measure: Beats per minute
Heart Rate Variability (HRV)
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Wearable-derived heart rate variability during the sleep episode, compared between groups. Unit of Measure: Milliseconds
8 secondary outcomes
PROMIS Sleep Disturbance score
Time frame: Upon waking, at each of 3-4 post-night-shift sleep episodes per participant
Karolinska Sleepiness Scale (KSS) score
Time frame: Upon waking, at each of 3-4 post-night-shift sleep episodes per participant
Sleep Onset Latency
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Incidence of Skin Irritation and Adverse Events Associated with Patch Use
Time frame: Time Frame: From first patch application through study completion, up to 8 weeks
Wake After Sleep Onset (WASO)
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Respiratory Rate During Sleep
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Peripheral Oxygen Saturation (SpO₂) During Sleep
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Device-Reported Stress Score
Time frame: Time Frame: Each post-night-shift sleep episode, up to 4 episodes per participant
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Background: PubMed 2265922Akerstedt T, Gillberg M. Subjective and objective sleepiness in the active individual. Int J Neurosci. 1990 May;52(1-2):29-37. doi: 10.3109/00207459008994241.
- Background: PubMed 22250775Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, Johnston KL, Pilkonis PA. Development of short forms from the PROMIS sleep disturbance and Sleep-Related Impairment item banks. Behav Sleep Med. 2011 Dec 28;10(1):6-24. doi: 10.1080/15402002.2012.636266.
- BackgroundGudin J, Dietze D, Dhaliwal G, Hurwitz P. "Haptic Vibrotactile Trigger Technology: Disrupting the Neuromatrix to Reduce Pain Severity and Interference: Results from the HARMONI Study." Anesth Pain Res. 2022;6(1).
- Background: PubMed 41041253Fason J, Gudin J, Hurwitz P. Decreased anxiety through haptic technology patch usage: A case-control comparison. J Family Med Prim Care. 2025 Aug;14(8):3529-3537. doi: 10.4103/jfmpc.jfmpc_1981_24. Epub 2025 Sep 24.
- BackgroundDoghramji P, Dietze A. "Improving Sleep and Quality of Life after Use of a Haptic Vibrotactile Trigger Technology, Drug-Free, Topical Patch: Results from the HARMONI Study." Int J Family Med Healthcare. 2023;2(1).
- Individual participant dataSharing planned: No. Here's a short, submission-ready description you can paste into the IPD Sharing Statement field: Individual participant data will not be shared. This is a small Phase 1 feasibility study (N=20) conducted within a narrowly defined population (NHS doctors on night-shift rotations in the UK), where the limited sample size and specificity of the population create a meaningful risk of participant re-identification, even after de-identification. Data collected are intended solely to assess feasibility and generate preliminary effect-size estimates to inform the design of a future randomized controlled trial, consistent with the scope of participant consent obtained for this study. Data will be handled in accordance with UK GDPR, including data minimization and pseudonymization safeguards.
Related trials for Shift Work Sleep Disorder
Not yet recruitingObservational study
Circadian Clock Proteins in Gingival Crevicular Fluid of Individuals With and Without Circadian Rhythm Disruption
Gingivitis, Circadian Rhythm Disruption
Recruiting
Role of Sleep Reactivity in Shift Work Disorder
Shift-work Disorder
Not yet recruitingObservational study
Sleep, Mindfulness, and Shift-Level Safety Performance in Perianesthesia Nurses
Sleep, Fatigue
RecruitingPhase 4
Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance
Shift Work Schedule, Circadian Rhythm
Recruiting
Shift Workers' Health Behavior Action Program Across Europe
Night Shift Work, Obesity & Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SuperPatch REM Patch in people with Shift Work Sleep Disorder and Shift Work Type Circadian Rhythm Sleep Disorder, run by SuperPatch Limited LLC at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of study procedures (recruitment) (time frame: Time Frame: Throughout the recruitment period, up to 8 weeks). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07785960, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.